Sayali Onkar
Senior Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Immunotherapies like immune checkpoint inhibitors (ICI) have changed the standard of care for patients with cancer, often leading to durable responses. However, many patients remain or become refractory to ICIs owing to factors such as a lack of primed neoantigen-reactive T cells. We developed a peptide-based vaccination platform that utilizes fully personalized genome vaccines (PGV) and targets neoantigens predicted by our OpenVax computational pipeline. In this study, we report results from the PGV001 study (NCT02721043) targeting up to 10 neoantigens, administered in the adjuvant setting to patients with both solid and hematologic malignancies who have high risk of recurrence. Our data indicate that PGV001 is feasible and safe, with 13 of 14 enrolled patients receiving the vaccine and 11 completing the treatment. 100% of vaccinated patients developed targeted T-cell and B-cell responses, highlighting the capacity of OpenVax to predict immunogenic neoantigens and the potential of PGV001 for safely inducing targeted immunity. Significance: The PGV001 platform is feasible, safe, and immunogenic. The OpenVax pipeline predicted immunogenic neoantigens in tumors with wide-ranging mutational burdens. Data from this study prompted three additional PGV001 trials, one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an ICI, and another in prostate cancer.
Year:
2025
Immunotherapies like immune checkpoint inhibitors (ICI) have changed the standard of care for patients with cancer, often leading to durable responses. However, many patients remain or become refractory to ICIs owing to factors such as a lack of primed neoantigen-reactive T cells. We developed a peptide-based vaccination platform that utilizes fully personalized genome vaccines (PGV) and targets neoantigens predicted by our OpenVax computational pipeline. In this study, we report results from the PGV001 study (NCT02721043) targeting up to 10 neoantigens, administered in the adjuvant setting to patients with both solid and hematologic malignancies who have high risk of recurrence. Our data indicate that PGV001 is feasible and safe, with 13 of 14 enrolled patients receiving the vaccine and 11 completing the treatment. 100% of vaccinated patients developed targeted T-cell and B-cell responses, highlighting the capacity of OpenVax to predict immunogenic neoantigens and the potential of PGV001 for safely inducing targeted immunity. Significance: The PGV001 platform is feasible, safe, and immunogenic. The OpenVax pipeline predicted immunogenic neoantigens in tumors with wide-ranging mutational burdens. Data from this study prompted three additional PGV001 trials, one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an ICI, and another in prostate cancer.
Year:
2025
Supplementary Fig2. PGV001-induced T cell immunity as measured by ex vivo IFNγ ELISPOT assay PBMC samples were stimulated with neoantigen peptides (pools of peptides: composed of 15mer OLPs+ 9-10mer predicted Mins corresponding to each vaccine SLP) and analyzed by IFNγ ELISPOT. All data is MOG normalized. a) Line diagrams showing longitudinal changes in IFNγ secretion upon stimulation with responder neoantigen peptides in each patient. Each line represents an individual neoantigen and each dot represents an individual time-point. For definition of “Responder” neoantigen: See Materials and Methods. b) Aligned dot plot showing IFNγ secretion at baseline (Pre) induced by all 126 neoantigens used in the study for 13 patients. Horizontal dotted line depicts cut-off threshold for immunogenicity in the assay. Peptides with immunogenicity at baseline, above the dotted line, are labeled. “Immunogenic” neoantigen: See Materials and Methods. c) Line plot showing post-vaccination immune response, as measured by IFNγ release in ex vivo ELISPOT assay, by the neoantigen peptides found to be “immunogenic” at baseline in (b). d) Plot showing number of IFNγ SFCs/million PBMCs elicited by tetanus peptide at various time points in 13 patients. e) Line plots showing immune response, as measured by IFNγ release in ex vivo ELISPOT assay, elicited by mutated neoantigen peptide pools vs their wild type (WT) counterparts at Week 28 over a range of peptide concentrations. Note: For PID:016 Week 31 sample was used. f) Kaplan Meier Curve comparing OS between subjects that responded, in ex vivo ELISPOT assay, to more or less than 40% neoantigens in their vaccines. PID-017 was lost of follow up and excluded from this analysis. g) Comparing number of SFCs/million PBMCs elicited by each neoantigen in patients Alive (N=6) or Deceased (N=4) at 60-month survival follow up. Total 96 neoantigens analyzed. h) Pie chart showing proportion of neoantigens that elicited antigen specific response in patients within Alive (N=6) vs Deceased (N=4) cohorts. SFC: spot forming cells. In f-h patients that expired with no evidence of their disease recurrence are excluded. *p value indicates two-sided Student’s T-test. ***
Year:
2025
Supplementary Fig7. Characterizing peripheral cellular immune environment in patients receiving PGV001. Multicolor flowcytometry performed to phenotype circulating immune cells in patients and healthy donors (HD). PID-017 was excluded from analysis. a) Tabulated view of age and sex of the seven healthy donors whose PBMCs are used in the study. b) Frequency of lymphoid immune cell subsets over the course of treatment. Each dot represents a subject. # p value indicates un-paired two-sided Student’s T-test comparing HD with patient cohort #
Year:
2025
Supplementary Fig5. TCR sequencing on neoantigen reactive T cells in patient PBMCs a) (Top) Depiction of methodology utilized to generate ex vivo and in vitro expanded and stimulated (IVS) T cell samples from screen, week 8 (W8) and week 28 (W28) timepoints for TCR sequencing. (Bottom) Gating strategy and representative dot plot for isolation by FAC sorting of IFNγ positive, neoantigen reactive T cells for TCR sequencing. b) (Top) Representative differential abundance plots from PID:012 comparing TCR clones between two conditions listed on X and Y axes. (Bottom) Logic and calculation of “relevant” clones in vivo. First using the IVS T cells, lists of TCR sequences differentially abundant in peptide stimulated (Pepstim) Week 8 (W8) and Week 28 (W28) versus screening were generated, named W8IVS>scr and W28IVS>scr, respectively. Similarly, lists of TCR sequences differentially abundant in peptide expanded W8 and W28 samples versus DMSO expanded cells was obtained, named W8ctrl>IVS and W28ctrl>IVS, respectively. Sequences in W8ctrl>IVS and W28ctrl>IVS were removed from W8IVS>scr and W28IVS>scr to obtain vaccine induced “relevant” TCR sequences in IVS T cells named, W8ΔIVS and W28ΔIVS. Ex vivo T cells were analyzed to identify lists of differentially abundant TCRs in W8 and W28 versus screening, named W8ex>scr and W28ex>scr. Finally, an intersection between relevant clones in IVS (W8ΔIVS and W28ΔIVS) and abundant clones in W8 or W28 ex vivo T cells (W8ex>scr and W28ex>scr) was performed to identify relevant neoantigen reactive TCR sequences in vivo, named W8clones and W28clones. c) Stacked bar plot depicting number and frequency of new (detected only post vaccination) and expanded (existed at baseline but frequency expanded post vaccination) W8clones and W28clones TCR clones in PID:015. Each color represents distinct TCR clones and the height of each stack represents each clone’s frequency. d) For PID:015, Venn diagram showing overlap between ex vivo and IVS clones to obtain W8clones and W28clones and their overlap to identify persisting clones in vivo. For PID:015, no persisting clones were found.
Year:
2025
Supplementary Fig1. PGV001 feasibility and recurrence free survival a) Survival plot depicting overall survival (OS). N=12. Median survival depicted by vertical dotted line b) Survival plot depicting recurrence free survival (RFS). Median RFS is depicted by vertical dotted line. N=12. c) Swimmer plot depicting time-line of clinical events for each patient since their curative intent treatment. d) Comparing linear correlation between TMB or neoantigen load vs OS at 60 months from 1st vaccine. Pearson correlation coefficient (r) calculated for fitting of the correlation with 95% confidence interval (95%CI). TMB: tumor mutation burden, NeoAg: neoantigens, OS: overall survival,
Year:
2025
Supplementary Fig4. CD4+ and CD8+ T cell activation by PGV001 PBMCs from patients were expanded in vitro in presence of neoantigen peptides (pools of peptides, OLPs+Mins, corresponding to each vaccine SLP) and restimulated with peptide/s followed by intracellular staining and flowcytometry. All data is normalized to MOG. a) Aligned dot plot showing CD8+ and CD4+ T cell responses at baseline induced by 96 evaluated neoantigens across 10 patients. Horizontal dotted line depicts cut-off threshold for immunogenicity. 15 and 32 peptides were found to be immunogenic at baseline against CD8+ and CD4+ T cells, respectively. b) Line plots showing longitudinal CD8+ and CD4+ T cell immune responses induced by neoantigens found to be immunogenic at baseline in (a) and that induced greater than 2-fold increase in response following PGV001 treatment. c) Each pie chart shows proportion of vaccine peptides that induced production of IFNγ, TNFα or IL-2 in CD8+ or CD4+T cells in each patient at any timepoint post vaccine initiation. Refer to Material and Methods for definition of “response” in flowcytometry assay. d) CD8+ and CD4+ T cell immune responses elicited by tetanus peptides at various time points in 10 evaluated patients.
Year:
2025
Supplementary Fig3. Neoantigen specific antibody responses induced by PGV001. Patient plasma was subjected to seromics by ELISA using linear SLPs in the vaccines. N=12 patients. PID-017 excluded from analysis due to high background. a) Stacked bar graph depicting number of neoantigens that induced an IgG/A or M response in each patient at Week 8 and Week 28. For seromics by ELISA a “Responder” neoantigen is defined as a peptide that induced an antibody titer of greater than 100 compared to baseline. b) Line diagrams showing changes in antibody isotypes induced by responder peptides in patients from pre-treatment (Pre), through Prime (Week 8) and Post (Week 28, Week 31 or End of treatment (EOT)). c) Line graph showing changes in titers of total IgG-subclasses induced by responder peptides in PID-006 and PID-008. d) Heat map depicting poly-ICLC specific antibody responses in each patient. e) Plot depicting linear correlation between total IgG antibody titer and IFNγ ELISPOT response at Week 8 (Prime) and Week 28/31 (Post). Pearson correlation coefficient and Spearman correlation coefficient calculated for fitting of the correlation with 95% confidence interval (95%CI). Each dot represents a neoantigen. Horizontal line depicts threshold for antibody titer response at 100. The vertical dotted line depicts threshold for ELISPOT immunogenicity at 60 SFC/million PBMCs. For Week 8, 126 neoantigens evaluated while for Week 28/31, 116 neoantigens were evaluated.
Year:
2025
Breast cancer, the most common type of cancer affecting women, encompasses a collection of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical presentation, disease trajectories, treatment options, and outcomes. Immunotherapy has revolutionized treatment for some solid tumors but has shown limited promise for breast cancers. In this review, we summarize recent advances in our understanding of the complex interactions between tumor and immune cells in subtypes of breast cancer at the cellular and microenvironmental levels. We aim to provide a perspective on opportunities for future immunotherapy agents tailored to specific features of each subtype of breast cancer. Significance: Although there are currently over 200 ongoing clinical trials testing immunotherapeutics, such as immune-checkpoint blockade agents, these are largely restricted to the triple-negative and HER2+ subtypes and primarily focus on T cells. With the rapid expansion of new in vitro, in vivo, and clinical data, it is critical to identify and highlight the challenges and opportunities unique for each breast cancer subtype to drive the next generation of treatments that harness the immune system.
Year:
2022
Collaborators (11)
Cansu Cimen Bozkus
Purdue University
Marshall Posner
National Cancer Center Hospital
Ana Acuna-Villaorduna
Assistant Professor
Icahn School of Medicine at Mount Sinai
Robert Sebra
Professor
Icahn School of Medicine at Mount Sinai
Brett A. Miles DDS MD FACS
Professor
Northwell Health
Alex Rubinsteyn
Assistant Professor
University of North Carolina at Chapel Hill
Steffi Oesterreich
UPMC Hillman Cancer Center
Jeffrey Hammerbacher
Assistant Professor
Medical University of South Carolina
Samir Parekh
Director, Center of Excellence for Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Nina Bhardwaj
Director of Cancer Immunotherapy, Professor of Medicine, Ward-Coleman Chair in Cancer Researc
Icahn School of Medicine at Mount Sinai
Matthew D. Galsky
Radboud University Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.